Page last updated: 2024-09-03

sri 62-834 and Acute Promyelocytic Leukemia

sri 62-834 has been researched along with Acute Promyelocytic Leukemia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dive, C; Watson, JV; Workman, P1
Donaldson, J; Lohmeyer, M; Workman, P1

Other Studies

2 other study(ies) available for sri 62-834 and Acute Promyelocytic Leukemia

ArticleYear
Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells.
    Cancer research, 1991, Feb-01, Volume: 51, Issue:3

    Topics: Animals; Antineoplastic Agents; Azepines; Cell Division; Cell Membrane Permeability; Flow Cytometry; Furans; Humans; Hydrogen-Ion Concentration; Leukemia, Promyelocytic, Acute; Mammary Neoplasms, Animal; Mice; Phospholipid Ethers; Platelet Activating Factor; Time Factors; Triazoles; Tumor Cells, Cultured

1991
Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-methyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells.
    Biochemical pharmacology, 1991, Jan-15, Volume: 41, Issue:2

    Topics: Antineoplastic Agents; Azepines; Calcium; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Furans; Humans; Leukemia, Promyelocytic, Acute; Phospholipid Ethers; Platelet Activating Factor; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured

1991